Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
|
| gptkbp:alsoKnownAs |
N-803
|
| gptkbp:clinicalTrialPhase |
Phase 2
NCT02138734 NCT03022825 |
| gptkbp:combinationTherapy |
gptkb:BCG
checkpoint inhibitors |
| gptkbp:developedBy |
gptkb:ImmunityBio
gptkb:Altor_BioScience |
| https://www.w3.org/2000/01/rdf-schema#label |
ALT-803
|
| gptkbp:indication |
immunotherapy
bladder cancer non-muscle invasive bladder cancer |
| gptkbp:macromoleculeType |
gptkb:protein
|
| gptkbp:mechanismOfAction |
IL-15 superagonist
immune system modulator |
| gptkbp:regulates |
investigational
|
| gptkbp:routeOfAdministration |
subcutaneous
intravesical |
| gptkbp:sideEffect |
fever
fatigue injection site reaction |
| gptkbp:target |
gptkb:natural_killer_cells
gptkb:CD8+_T_cells |
| gptkbp:bfsParent |
gptkb:Altor_BioScience
gptkb:interleukin-15 |
| gptkbp:bfsLayer |
8
|